Experts support continued use of Aranesp in certain kidney patients

10/18/2010 | Bloomberg

An FDA advisory panel voted 15-1 for continued use of Amgen's Aranesp in nondialysis patients with chronic kidney disease. The panel also voted 9-5 against lowering dosing for patients with blood hemoglobin levels less than 9 grams per deciliter. The advisers recommended further studies to determine the ideal dosing and to identify which patients benefit from Aranesp.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations